lasmiditan

Lasmiditan is a prescription medication approved for the acute treatment of migraine with or without aura in adults. It is the first-in-class selective serotonin 5-HT1F receptor agonist, a member of the ditan class. By activating 5-HT1F receptors in the trigeminal system, lasmiditan is thought to inhibit the release of neuropeptides such as CGRP and to dampen pain signaling, without causing cerebral vasoconstriction.

Lasmiditan is marketed under the brand name Reyvow. It is taken orally as a single dose at the onset of a migraine attack, with available strengths of 50 mg, 100 mg, and 200 mg. A second dose within 24 hours is not recommended. The drug is intended for adults and is used to provide relief from migraine symptoms rather than as a preventive therapy. Because of its central nervous system effects, patients are advised that impairment, including dizziness and somnolence, can occur.

Common adverse effects include dizziness, fatigue, somnolence, paresthesias, and nausea. Because lasmiditan can impair activity and coordination, patients should avoid driving or operating heavy machinery for at least 8 hours after dosing. Cautions and potential interactions include avoidance of concomitant serotonergic medications and consideration of hepatic function, pregnancy, and other individual risk factors. Lasmiditan represents an alternative for patients who may not be suitable candidates for triptans due to cardiovascular concerns or contraindications to vasoconstriction.